LQDA
$74.44
+$2.31 (3.20%)+3.20%
ClosedLoading chart...
IndexN/A
Market Cap6.62B
Enterprise Value2.98B
Income$-0.04B
Sales$0.00B
EmployeesN/A
P/E531.71
P/S18.75
P/B66.33
P/C-74.16
EV/EBITDA-68.84
EV/SalesN/A
EPS (ttm)0.14
EarningsN/A
Gross Margin91.64%
Oper. Margin-32.45%
Profit Margin-43.53%
Volume2.52M
Shs Outstand0.09B
Change3.25%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.00M | $17.49M | $15.94M | $12.85M | $739.63K | $8.07M | $2.71M | $7.26M |
| Cost of Revenue | $5.88M | $2.89M | $2.86M | $3.02M | $237.71K | $807.19K | $121.39K | $319.76K |
| Gross Profit | $8.12M | $14.60M | $13.08M | $9.83M | $501.92K | $7.26M | $2.59M | $6.94M |
| Gross Margin | 58.00% | 83.49% | 82.06% | 76.48% | 67.86% | 90.00% | 95.52% | 95.59% |
| Operating Expenses | $129.41M | $87.98M | $51.85M | $43.63M | $59.59M | $54.09M | $37.45M | $34.97M |
| Operating Income | $-121.29M | $-73.38M | $-38.77M | $-33.80M | $-59.09M | $-46.82M | $-34.87M | $-28.03M |
| Operating Margin | -866.63% | -419.62% | -243.30% | -262.95% | -7989.03% | -580.07% | -1288.08% | -386.16% |
| Net Income | $-130.39M | $-78.50M | $-41.02M | $-34.58M | $-59.76M | $-47.58M | $-53.14M | $-29.15M |
| Net Margin | -931.65% | -448.89% | -257.39% | -269.03% | -8080.11% | -589.48% | -1962.92% | -401.68% |
| EPS (Basic) | $-1.66 | $-1.21 | $-0.67 | $-0.70 | $-1.76 | $-2.51 | $-7.42 | $-3.40 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $230.31M | $118.33M | $129.20M | $93.73M | $99.53M | $68.84M | $49.42M | $14.84M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $153.04M | $71.04M | $38.78M | $28.46M | $28.45M | $33.89M | $30.73M | $48.54M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $77.28M | $47.29M | $90.42M | $65.27M | $71.09M | $34.95M | $18.69M | $-33.69M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $77.28M | $47.29M | $90.42M | $65.27M | $71.09M | $34.95M | $18.69M | $-33.69M |
| Total Liabilities & Stockholders Equity | $230.31M | $118.33M | $129.20M | $93.73M | $99.53M | $68.84M | $49.42M | $14.84M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-130.39M | $-78.50M | $-41.02M | $-34.58M | $-59.76M | $-47.58M | $-53.14M | $-29.15M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-93.42M | $-41.56M | $-28.59M | $-34.03M | $-54.14M | $-48.28M | $-31.83M | $-24.29M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Why Liquidia Stock Was Diving This WeekThe Motley Fool Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsightGlobeNewswire Inc. Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock?The Motley Fool The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8MThe Motley Fool Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual MeetingBenzinga Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsightGlobeNewswire Inc. U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)GlobeNewswire Inc. Liquidia Corporation Provides Update on Litigation Filed by United TherapeuticsGlobeNewswire Inc.
Show 12 more stories
District Court Dismisses Dispute Filed by United Therapeutics Against LiquidiaGlobeNewswire Inc. Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025GlobeNewswire Inc. Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of DirectorsGlobeNewswire Inc. Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsightGlobeNewswire Inc. United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ PatentGlobeNewswire Inc. Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)GlobeNewswire Inc. U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)GlobeNewswire Inc. Liquidia corp chief medical officer sells $18.4k in stock - Investing.comInvesting.com Liquidia Corp executive sells shares worth over $19,000 - Investing.comInvesting.com Liquidia Corp executive sells over $14k in company stock - Investing.comInvesting.com Voip-pal director Kevin Williams sells shares worth $19,234 By Investing.com - Investing.comInvesting.com Forecasting The Future: 5 Analyst Projections For LiquidiaBenzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Discover more
You may be interested in